Moreover, in pancreatic cancer, KRAS activates Src in a pseudopodium-enriched atypical kinase 1 (PEAK1)-dependent manner or directly cooperates with Src, leading to metastatic tumor growth, therapy resistance, and accelerated tumorigenesis [35, 36]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.